Amarin Corp Plc (AMRN)

[CaptBeer]

Sometimes we get lost in trying to gauge how VAZKEPA® is doing in England, and it’s unfair to compare CVD drugs with differing targets, dosage, formulations, and delivery systems. Not to mention “Delta T”, Time in the Market. Nevertheless, using data from NHS I’ve put together a list of non-statins where I estimated the unit cost (per capsule, per tablet, per injection etc.) and multiplied that number by the total units dispensed in July 2023.

You can see the average price per pill (Omacor, Nexletol, VAZKEPA and the average price per injection (Leqvio, Repatha and Praluent) and the resulting Sales in July. Furthermore, you can also see the market shares for these products.

The overall lipid lowering therapy market is huge and is dominated by statins (93%). VAZKEPA® holds a 15% market share in the non-statin segment. Not bad for a New-comer!”